Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Craig Miller

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Journal of Experimental & Clinical Cancer Research : CR|August 21, 2024
Identification of circulating tumor cells captured by the FDA-cleared Parsortix<sup>®</sup> PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluationsMariacristina Ciccioli, Kyukwang Kim, Negar Khazan, et al.
Gynecologic Oncology|September 15, 2015
Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic massElizabeth Lokich, Marguerite Palisoul, Nicole Romano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseasesW Jeffrey Allard, Jeri Matera, M Craig Miller, et al.
Gynecologic Oncology|October 15, 2008
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massRichard G Moore, D Scott McMeekin, Amy K Brown, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 27, 2021
Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumorsAlexandra Blackman, Jessica Mitchell, Rachael Rowswell-Turner, et al.
Urologic Oncology|March 20, 2003
DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCCIhor S Sawczuk, Cynthia L Pickens, Usha R Vasa, et al.
American Journal of Obstetrics and Gynecology|May 18, 2010
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massRichard G Moore, Moune Jabre-Raughley, Amy K Brown, et al.
Gynecologic Oncology|December 7, 2007
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic massRichard G Moore, Amy K Brown, M Craig Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survivalDaniel F Hayes, Massimo Cristofanilli, G Thomas Budd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancerG Thomas Budd, Massimo Cristofanilli, Mathew J Ellis, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Journal of Experimental & Clinical Cancer Research : CR|August 21, 2024
Identification of circulating tumor cells captured by the FDA-cleared Parsortix<sup>®</sup> PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluationsMariacristina Ciccioli, Kyukwang Kim, Negar Khazan, et al.
Gynecologic Oncology|September 15, 2015
Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic massElizabeth Lokich, Marguerite Palisoul, Nicole Romano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseasesW Jeffrey Allard, Jeri Matera, M Craig Miller, et al.
Gynecologic Oncology|October 15, 2008
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massRichard G Moore, D Scott McMeekin, Amy K Brown, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 27, 2021
Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumorsAlexandra Blackman, Jessica Mitchell, Rachael Rowswell-Turner, et al.
Urologic Oncology|March 20, 2003
DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCCIhor S Sawczuk, Cynthia L Pickens, Usha R Vasa, et al.
American Journal of Obstetrics and Gynecology|May 18, 2010
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massRichard G Moore, Moune Jabre-Raughley, Amy K Brown, et al.
Gynecologic Oncology|December 7, 2007
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic massRichard G Moore, Amy K Brown, M Craig Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survivalDaniel F Hayes, Massimo Cristofanilli, G Thomas Budd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancerG Thomas Budd, Massimo Cristofanilli, Mathew J Ellis, et al.
Pageof 6